Oncocyte Corp Quarterly Debt-to-equity in % from Q3 2016 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Oncocyte Corp quarterly Debt-to-equity history and growth rate from Q3 2016 to Q2 2024.
Oncocyte Corp Debt-to-equity for the quarter ending June 30, 2024 was 211 %, a 87.9% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	211	+98.5	+87.9%	Jun 30, 2024
Q1 2024	163	+51.4	+46.2%	Mar 31, 2024
Q4 2023	121	-1.75	-1.43%	Dec 31, 2023
Q3 2023	117	-3.93	-3.24%	Sep 30, 2023
Q2 2023	112	+2.01	+1.83%	Jun 30, 2023
Q1 2023	111	+10.2	+10.1%	Mar 31, 2023
Q4 2022	123	+52.9	+75.8%	Dec 31, 2022
Q3 2022	121	+66.1	+120%	Sep 30, 2022
Q2 2022	110	+58.8	+114%	Jun 30, 2022
Q1 2022	101	+58.2	+136%	Mar 31, 2022
Q4 2021	69.7	+6.13	+9.64%	Dec 31, 2021
Q3 2021	55	-0.64	-1.15%	Sep 30, 2021
Q2 2021	51.4	+7.95	+18.3%	Jun 30, 2021
Q1 2021	42.7	+12.4	+41%	Mar 31, 2021
Q4 2020	63.6	+48.4	+317%	Dec 31, 2020
Q3 2020	55.7	+39.2	+238%	Sep 30, 2020
Q2 2020	43.4	+20.3	+87.5%	Jun 30, 2020
Q1 2020	30.3	-5.98	-16.5%	Mar 31, 2020
Q4 2019	15.3	-72	-82.5%	Dec 31, 2019
Q3 2019	16.5	-66.7	-80.2%	Sep 30, 2019
Q2 2019	23.2	-61.3	-72.6%	Jun 30, 2019
Q1 2019	36.3	-56.2	-60.8%	Mar 31, 2019
Q4 2018	87.2	-5.54	-5.97%	Dec 31, 2018
Q3 2018	83.1	+9.84	+13.4%	Sep 30, 2018
Q2 2018	84.5	+25.9	+44.1%	Jun 30, 2018
Q1 2018	92.5	+41.9	+82.6%	Mar 31, 2018
Q4 2017	92.8	+50.1	+117%	Dec 31, 2017
Q3 2017	73.3	+37.9	+107%	Sep 30, 2017
Q2 2017	58.6			Jun 30, 2017
Q1 2017	50.6			Mar 31, 2017
Q4 2016	42.7			Dec 31, 2016
Q3 2016	35.4			Sep 30, 2016

* An asterisk sign (*) next to the value indicates that the value is likely invalid.